TORONTO, CANADA — (May 6, 2020) — Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) is pleased to announce the hiring of Dr. Joseph Stauffer in the new role of Chief Medical Officer (“CMO”). An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number of chronic and acute pain assets. Dr. Stauffer will assume a leadership role in Antibe’s clinical development strategy and its increasing engagement with global regulatory agencies and potential large-market partners.
Dan Legault, Antibe’s CEO, remarked, “Joe’s hands-on knowledge of drug development for both chronic and acute pain, and his stature in pharmaceutical and regulatory circles, made him our top choice as CMO. In particular, his commercial awareness and expertise in analgesic trial design will serve as a great asset as we shift our focus to late-stage clinical development and partnering opportunities for the large markets. We are delighted to welcome Joe to the Antibe team.”
Following his medical training, Dr. Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (“FDA”) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director. Over the succeeding years, Dr. Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than $250 million for Cara Therapeutics, a developer of novel chemical entities to treat post-operative pain and chronic itch in Chronic Kidney Disease.
“The world is in desperate need of safer therapies for pain and inflammation,” said Dr. Stauffer. “Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development, and ultimately providing patients with a safer treatment paradigm for pain management.”
Dr. Stauffer earned his medical degree from the Philadelphia College of Osteopathic Medicine and completed his anesthesiology residency at Johns Hopkins University Hospital, where he maintained a part-time Assistant Professorship until 2016. He earned his MBA degree in a joint program at New York University, the London School of Economics in the UK, and the Hautes Etudes Commerciales management school in Paris, France. Dr. Stauffer is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (“IMMPACT”), which became an official public-private partnership among pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the USA.
In connection with Dr. Stauffer’s appointment, the Company granted a total of 500,000 restricted share units (“RSUs”). All RSUs are subject to time-based vesting; one-third of the RSUs granted will vest on each of the first, second and third anniversaries of today’s date.
About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves the linking of a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace. www.antibethera.com
Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the proposed licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar wording. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s inability to secure additional financing and licensing arrangements on reasonable terms, or at all, its inability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.
Antibe Therapeutics Inc.
VP Investor Relations
Read all news